David Southwell

We have a pill that treats cancer.

And, you know, I think they understand that.

I think they're very excited

about the biomarker approach.

I find that in the particular case of Velastra, they kind of understand it.

When you're in cell therapy, it's much more difficult because it's very complicated.

They ask you about manufacturing.

Are you going to be able to manufacture it?

What's it going to cost to manufacture it at scale?

How much do we have to give you to build the facility to manufacture it at scale?

And I'm also on the board of a gene therapy company.

And these are questions that they get asked all the time and they're very good at answering them.

But it's a, when you have a small molecule, you know, we can talk about the chemistry of the particular pills that we're giving, but the manufacturing is very straightforward once you've got it sorted out.

And you know, the question is, does it work?

And so there are always kind of crux points in a conversation with an investor.

where you realize you have to get a particular point across.

And I think with us, it's translating the combination data into human data.

But the other real challenge I faced before JP Morgan is we found out about this biomarker a week before JP Morgan.

So we needed to put, we said, all right, we've got a really good explanation as to why this works and how important it could be.

we need to put together slides that explain that.